EN DE
Watch Zhejiang Chimin Pharm Co Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Zhejiang Chimin Pharm Co Ltd (603222) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Zhejiang Chimin Pharm Co Ltd stock ¥5.62, price ¥7.10, that is 20.8% below the price, quality 38 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare CN · ISIN CNE100002193

ZC Zhejiang Chimin Pharm Co Ltd logo Thin data Nov 10, 2026

Zhejiang Chimin Pharm Co Ltd

603222 · SHG
Expensive, weak quality

Our calculation puts a fair price 21% below what the stock costs today.

Low debt
Profit last quarter 56% below a year ago.
Fair value ¥5.62 · Overvalued
Quality 38/100
Weak Growth (revenue 5y −4.8 %/yr in CNY)
Loss-making · -36.9% net margin (TTM)
Negative free cash flow
Trails peers (0/11)
Narrow moat 12/100
Thin data
Estimate
Watch Zhejiang Chimin Pharm Co Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

¥15.85 ¥5.04 Fair Value ¥5.62 Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range ¥5.04 – ¥15.85 · fair‑value band ¥4.22 – ¥7.03 · the ¥7.10 price screens above the ¥5.62 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow Zhejiang Chimin Pharm Co in your weekly email

Every Wednesday you see whether Zhejiang Chimin Pharm Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Chimin Health Management Co., Ltd., together with its subsidiaries, researches, develops, produces, and sells vitro diagnostic products and provides medical services in China and internationally.

Show moreShow less

The company provides non-PVC double-tube double-valve, single-tube single-valve, and single-tube double-valve soft bags; plastic bottles; and other packaging forms.

It also offers medical instruments, including safety syringes, safety injection needles, sterile syringes, dispensers, insulin syringes, infusion sets, precision filter infusion sets, and other products.

In addition, the company provides in vitro diagnostics products, such as clinical chemical diagnostic, immunological diagnostic, blood testing, rapid diagnostic, and enzyme-linked immunological diagnostic reagents; laboratory instruments; and in vitro diagnostic medical products, as well as FOB fecal occult blood automated immunoassay monitoring and pylori Helicobacter detection kits.

Further, it offers hemodialysis series products, including hemodialysis concentrate, hemodialysis tubing, and other products; and medical and health services.

The company was formerly known as Zhejiang Chimin Pharmaceutical Co.,Ltd. and changed its name to Chimin Health Management Co., Ltd. in August 2018. Chimin Health Management Co., Ltd. was founded in 1996 and is based in Taizhou, China.

Stock analysis

Zhejiang Chimin Pharm Co Ltd (603222) currently trades at ¥7.10, while our estimate is ¥5.62, 21% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: ¥4.22 (bear) to ¥7.03 (bull), the price of ¥7.10 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 38/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Zhejiang Chimin Pharm Co Ltd reported revenue of 686M CNY in FY2025 versus 1.1B CNY in FY2021, a compound −11.1%/yr. Reported net income was −246M CNY in FY2025.

Key figures

Market cap 3.7B CNY (≈ $559M) Small · P/S ratio 5.79 · EPS (TTM) ¥−0.4800 · Dividend yield 0.5% · Net margin −36.9% · Return on equity −18.4% · Return on assets (EBIT) 0.0% (5-year average) · Operating margin −10.7%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (medium confidence).

What moves the price

The share trades about 40% below its 52-week high and 5% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −45% fair-value upside, at −21%, 603222 screens cheaper than that median.

Fair Value

Bear ¥4.22 Fair Value ¥5.62 Bull ¥7.03
Price ¥7.10 · Downside -20.8%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 38/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 6
How much profit the company makes from its sales and capital
Quality Growth 8
Are margins and returns getting better?
Cashflow 3
Do the profits arrive as real cash?
Financial strength 67
Debt, balance sheet and risk of trouble
Investment 91
Does it invest with discipline instead of growing at any price?
Low Volatility 60
How calm the share price moves, does not count
Price momentum 15
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 5
Distance to the 52-week high, does not count
New shares 81
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−11.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−6.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−4.8%
Start year 2020 (pandemic). Over 10 years: +4.3% a year
Revenue growth 14 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.6%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
3.6% (2020) → −13.8% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

603222 screens overvalued: fair value 21% below the price. Compare with Intuitive Surgical, Inc →

Compare Zhejiang Chimin Pharm Co Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 196 stocks

Beats the industry median on 0/10 measures
Overall it trails its industry peers.
Valuation
Quality Score 38 · Bottom 25%
Fair Value upside −20.8% · Below median
Profitability
Return on assets −10.6% · Bottom 25%
Net margin (12 months) −36.9% · Bottom 25%
Operating margin (12 months) −10.7% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −5.9% · Bottom 25%
Dividend yield (12 months) 0.5% · Bottom 25%
Balance sheet
Debt / equity 0.20× · Above median

Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper

P/B 3.06× · Pricier than median
P/S (12 months) 5.67× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)6 · sector 21
FUTURE (revenue growth)0 · sector 40
PAST (return on equity)0 · sector 26
HEALTH (low debt)90 · sector 96
DIVIDEND (yield)10 · sector 32

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Solventum Corporation SOLV $90.08 $131.27 +46% vs 603222
EssilorLuxottica Société anonyme EL €187.60 €196.22 +5% vs 603222
Intuitive Surgical, Inc ISRG $450.04 $353.90 −21% vs 603222
Medline Inc MDLN $40.91 $28.59 −30% vs 603222
Alcon Inc ALC CHF 61.88 CHF 34.06 −45% vs 603222
Becton, Dickinson and Company BDX $212.61 $97.80 −54% vs 603222
Straumann Holding STMN CHF 106.85 CHF 45.50 −57% vs 603222
West Pharmaceutical Services, Inc WST $412.55 $139.22 −66% vs 603222
Sartorius Stedim Biotech S.A DIM €223.40 €54.82 −75% vs 603222
Sartorius Aktiengesellschaft SRT €227.00 €42.50 −81% vs 603222

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Zhejiang Chimin Pharm Co Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Zhejiang Chimin Pharm Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/603222

Frequently asked questions

Is Zhejiang Chimin Pharm Co Ltd (603222) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is ¥5.62 versus a price of ¥7.10, about 21% lower (overvalued).
What is the fair value of 603222?
Our estimate for Zhejiang Chimin Pharm Co Ltd is ¥5.62 (as of Nov 10, 2026), built from audited fundamentals. The current price: ¥7.10.
What is the quality score of 603222?
Zhejiang Chimin Pharm Co Ltd has a Quality Score of 38/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Zhejiang Chimin Pharm Co Ltd (603222)?
Our calculated price target is the estimate of ¥5.62 (as of Nov 10, 2026). Cautious scenario ¥4.22, optimistic scenario ¥7.03. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Zhejiang Chimin Pharm Co Ltd stock forecast for 2026?
Our estimate puts fair value at ¥5.62, about 21% lower versus a price of ¥7.10 (overvalued). Cautious scenario ¥4.22, optimistic scenario ¥7.03. The calculation is refreshed regularly with new filings.
What is the revenue of Zhejiang Chimin Pharm Co Ltd (603222)?
Zhejiang Chimin Pharm Co Ltd reported trailing-twelve-month revenue of about 657M CNY (latest available figure, as of Nov 10, 2026).
Does Zhejiang Chimin Pharm Co Ltd pay a dividend?
Zhejiang Chimin Pharm Co Ltd currently shows a dividend yield of 0.52% relative to its recent price (as of Nov 10, 2026).
How much is the dividend of Zhejiang Chimin Pharm Co Ltd (603222)?
Zhejiang Chimin Pharm Co Ltd has a dividend yield of 0.5%.
What is the intrinsic value of Zhejiang Chimin Pharm Co Ltd (603222)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Zhejiang Chimin Pharm Co Ltd it is ¥5.62 per share (as of Nov 10, 2026), against a price of ¥7.10.
Is Zhejiang Chimin Pharm Co Ltd stock overvalued or undervalued in 2026?
As of Nov 10, 2026, 603222 trades above its calculated fair value: price ¥7.10, fair value ¥5.62, a gap of about −21% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 603222?
No. The price is what the market pays today (¥7.10); the fair value is what the company's own numbers justify (¥5.62). For Zhejiang Chimin Pharm Co Ltd the two are ¥1.48 per share apart. That gap is exactly why we show both numbers side by side.
How much is Zhejiang Chimin Pharm Co Ltd worth?
The market values Zhejiang Chimin Pharm Co Ltd at about 3.7B CNY (market capitalisation, as of Nov 10, 2026). Per share that is ¥7.10; our models calculate a fair value of ¥5.62 per share.
What do the bullish and bearish scenarios say about 603222?
Our models span a range for Zhejiang Chimin Pharm Co Ltd: cautious scenario ¥4.22, base ¥5.62, optimistic ¥7.03 per share (as of Nov 10, 2026, price ¥7.10). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Zhejiang Chimin Pharm Co Ltd (603222)?
Balance-sheet figures for Zhejiang Chimin Pharm Co Ltd (as of Nov 10, 2026): return on equity −18.4%, debt of 0.20 per unit of equity. They feed the Quality Score of 38/100, which measures business quality independently of the share price.
How far is 603222 from its 52-week high?
Zhejiang Chimin Pharm Co Ltd trades at ¥7.10, about 40% below its 52-week high of ¥11.85 and 5% above the low of ¥6.75 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of ¥5.62 is for.
Which stocks are comparable to Zhejiang Chimin Pharm Co Ltd?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Becton, Dickinson and Company, Medline Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Zhejiang Chimin Pharm Co Ltd stock attractive at the current price?
The data as of Nov 10, 2026: price ¥7.10, calculated fair value ¥5.62 (−21%), Quality Score 38/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Zhejiang Chimin Pharm Co Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Zhejiang Chimin Pharm Co Ltd (603222)?
The closing price on Nov 10, 2026 was ¥7.10. Our estimate is ¥5.62, about 21% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Zhejiang Chimin Pharm Co Ltd right now?
Weak quality (38/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Zhejiang Chimin Pharm Co Ltd

How large is the market capitalisation of Zhejiang Chimin Pharm Co Ltd (603222)?
The market capitalisation of Zhejiang Chimin Pharm Co Ltd is 3.7B CNY (≈ $559M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Zhejiang Chimin Pharm Co Ltd (603222)?
The price-to-sales ratio of Zhejiang Chimin Pharm Co Ltd is 5.79 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Zhejiang Chimin Pharm Co Ltd (603222)?
Earnings per share at Zhejiang Chimin Pharm Co Ltd are ¥−0.4800. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Zhejiang Chimin Pharm Co Ltd (603222)?
The dividend yield of Zhejiang Chimin Pharm Co Ltd is 0.5%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Zhejiang Chimin Pharm Co Ltd (603222)?
The net margin of Zhejiang Chimin Pharm Co Ltd is −36.9% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Zhejiang Chimin Pharm Co Ltd (603222)?
The return on equity (ROE) of Zhejiang Chimin Pharm Co Ltd is −18.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Zhejiang Chimin Pharm Co Ltd (603222)?
On an EBIT basis the return on assets of Zhejiang Chimin Pharm Co Ltd is 0.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Zhejiang Chimin Pharm Co Ltd (603222)?
The operating margin of Zhejiang Chimin Pharm Co Ltd is −10.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Zhejiang Chimin Pharm Co Ltd (603222)?
Revenue at Zhejiang Chimin Pharm Co Ltd is growing −5.9% versus a year earlier (3y avg −6.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Zhejiang Chimin Pharm Co Ltd (603222)?
Earnings per share at Zhejiang Chimin Pharm Co Ltd are growing −56.1% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Zhejiang Chimin Pharm Co Ltd (603222) generate?
The free cash flow of Zhejiang Chimin Pharm Co Ltd is −56.6M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Zhejiang Chimin Pharm Co Ltd (603222) carry?
The net debt of Zhejiang Chimin Pharm Co Ltd is 338M CNY (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Zhejiang Chimin Pharm Co Ltd in the live analysis

One click puts Zhejiang Chimin Pharm Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.